1. KD. Tripathi. Antiadrenergic Drugs (Adrenergic Receptor Antagonists) and Drugs for Glaucoma. Essentials of medical pharmacology. Seventh edition. 2013. Page – 153.
2. Thomas C. Westfall and David P. Westfall. Adrenergic agonist and antagonist. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 326.
3. Gerald G. Briggs and Roger K. Freeman. T. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 3810-3812.
4. Santen Pharmaceutical Co., Ltd. DE-111 Against Timolol Ophthalmic Solution 0.5%. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on July 2015] [Accessed 13th January 2021] https://clinicaltrials.gov/ct2/show/NCT01342094
5. T J Zimmerman, M A Kass, M E Yablonski, B Becker. Timolol maleate: efficacy and safety. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. April 1979. [Accessed 13th January 2021] https://pubmed.ncbi.nlm.nih.gov/371597/#:~:text=Timolol%20applied%20topically%20twice%20daily,and%20safe%20ocular%20hypotensive%20agent.
6. A M Wagenvoort, J M van Vugt, M Sobotka, H P van Geijn. Topical timolol therapy in pregnancy: is it safe for the fetus? NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. December 1998. [Accessed 13th January 2021] https://pubmed.ncbi.nlm.nih.gov/9894675/
7. Brown & Burk UK Ltd. Electronic Medicines Compendium (EMC); [Revised on January 2020] [Accessed 13th January 2021] https://www.medicines.org.uk/emc/files/pil.10888.pdf
8. Valeant Pharmaceuticals International. U.S. Food & Drug Administration. [Revised on April 2016] [Accessed 13th January 2021]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018086s076lbl.pdf